Argenx Se ARGX
NASDAQ ARGX
$1,033.15 -20.31 (-1.93%)
At close: Sep 4, 2026 · 4:00 PM EDT

Argenx Se (ARGX) Common Equity (2015 - 2026)

Argenx Se's (ARGX) quarterly Common Equity came in at $8.4 billion in Q2 2026, down 99.86% on a YoY basis from $6095.8 billion in Q2 2025, and up 14.94% quarter-over-quarter from $7.3 billion in Q4 2025.

Analysis

Argenx Se (ARGX) Common Equity (2015 - 2026) Analysis & Trends

Argenx Se (ARGX) has reported Common Equity for 12 consecutive years, with $8.4 billion the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Common Equity fell 99.86% year-over-year to $8.4 billion; the trailing twelve-month figure through Jun 2026 stood at $8.4 billion (down 99.86% YoY), and the FY2025 full-year result was $7.3 billion, down 99.87% from the prior year.
  • Common Equity climbed to $8.4 billion in Q2 2026 per ARGX's latest filing, from $7.3 billion in the prior quarter.
  • Across five years, Common Equity topped out at $6095.8 billion in Q2 2025 and bottomed at $2.9 billion in Q2 2023.
  • Historically, Common Equity has averaged $1604.2 billion across 5 years, with a median of $7.3 billion in 2025.
  • The widest YoY moves for Common Equity: up 142917.33% in 2025, down 99.87% in 2025.
  • Over 5 years, Common Equity stood at $2813.7 billion in 2022, then sank by 99.85% to $4.1 billion in 2023, then jumped by 134086.06% to $5498.3 billion in 2024, then sank by 99.87% to $7.3 billion in 2025, then rose by 14.94% to $8.4 billion in 2026.
  • According to Business Quant data, Common Equity over the past three periods registered $8.4 billion, $7.3 billion, and $6095.8 billion for Q2 2026, Q4 2025, and Q2 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Common Equity (Qtr)
1 Amgen 236.37 Bn 222.38 Bn 7.24 Bn 11.69 Bn
2 Gilead Sciences 187.38 Bn 184.12 Bn 6.22 Bn 11.83 Bn
3 Vertex Pharmaceuticals 138.36 Bn 130.51 Bn 2.84 Bn 20.25 Bn
4 Regeneron Pharmaceuticals 85.09 Bn 77.10 Bn 3.93 Bn 31.71 Bn
5 Argenx Se 63.93 Bn 58.75 Bn 1.37 Bn 8.42 Bn
6 Moderna 58.07 Bn 52.94 Bn 52.00 Mn 6.76 Bn
7 Alnylam Pharmaceuticals 35.59 Bn 32.28 Bn 992.69 Mn 1.35 Bn
8 Biogen 32.63 Bn 31.34 Bn 1.96 Bn 18.85 Bn
9 Insmed 27.57 Bn 26.41 Bn 358.27 Mn 757.49 Mn
10 BioNTech SE 26.24 Bn 12.58 Bn 10.00 Mn 20.64 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 8.42 Bn
Dec 31, 2025 7.32 Bn
Jun 30, 2025 6,095.75 Bn
Dec 31, 2024 5,498.28 Bn
Jun 30, 2024 4.26 Bn
Dec 31, 2023 4.10 Bn
Jun 30, 2023 2.86 Bn
Dec 31, 2022 2,813.70 Bn
Jun 30, 2022 2.97 Bn
Dec 31, 2021 2,534.22 Bn
Jun 30, 2021 2.95 Bn
Dec 31, 2020 1,626.73 Bn
Jun 30, 2020 1.81 Bn
Dec 31, 2019 1.16 Bn
Jun 30, 2019 747.66 Mn
Dec 31, 2018 614.52 Mn
Jun 30, 2018 397.37 Mn
Dec 31, 2017 403.31 Mn
Jun 30, 2017 165.21 Mn
Dec 31, 2016 68.43 Mn